宫颈外植体模型用于HIV暴露前预防的药理学评价
研究比较宫颈内外组织药物代谢酶与转运体表达差异,并评估替诺福韦和恩曲他滨在外植体模型中的磷酸化及抗病毒效果。发现ABCC4和CYP3A5表达存在区域差异,胞内替诺福韦双磷酸浓度与病毒抑制相关,恩曲他滨剂量与感染比例相关。
要点
- 宫颈内外组织DMET表达存在差异,ABCC4在外宫颈低3倍,CYP3A5高2倍
- 替诺福韦双磷酸浓度与宫颈外病毒复制下降相关(r=0.39,P<0.05)
- 恩曲他滨剂量与感染外植体比例相关(P=0.02),但胞内三磷酸水平与保护无关
核心结论
- 宫颈内外组织在药物代谢酶和转运体表达及抗逆转录病毒代谢上存在差异。
- 宫颈外植体模型可一致地评估病毒感染性及药物剂量依赖性抑制。
- 该模型有助于确定替诺福韦双磷酸的目标浓度。
研究设计与样本
- 使用正常宫颈组织,通过qRT-PCR评估药物代谢酶和转运体基因表达。
- 将外植体与替诺福韦和恩曲他滨孵育,测量胞内代谢物。
- 用HIV-1JR-CSF攻击后,通过病毒RNA和p24测量感染性和剂量反应。
主要发现
- ABCC4在外宫颈组织表达比内宫颈低3倍,CYP3A5高2倍。
- IL-6与ABCB1(r=0.52,P=0.01)和ABCG2(r=0.56,P=0.005)相关。
- 内外宫颈的剂量归一化磷酸化无差异(P>0.5)。
- 外植体感染性低(53%),但不同部位无差异。
- 胞内替诺福韦双磷酸浓度与外宫颈病毒复制下降相关(r=0.39,P<0.05)。
临床怎么用
- 宫颈外植体模型可用于评估HIV暴露前预防药物的药效和确定替诺福韦双磷酸目标。
- 需考虑宫颈内外组织药物代谢差异对预防效果的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The female genital tract (FGT) is a unique compartment with physiologically distinct properties complicating the extrapolation of drug efficacy; critical gaps remain in understanding regional variability within the FGT itself. We performed an in-depth investigation across endo- and ectocervical tissues on the utility of the cervical explant model to evaluate pre-exposure prophylaxis (PrEP) efficacy. METHODS: Using normal cervical tissues, we evaluated gene expression of relevant drug metabolizing enzymes and transporters (DMETs) via qRT-PCR and compared ecto- and endocervix. To determine differences in drug phosphorylation and to assess antiretroviral (ARV) efficacy, we incubated explants in tenofovir and emtricitabine then measured intracellular metabolites. Viral infectivity and dose-response with ARVs was measured using viral RNA and p24 following HIV-1JR-CSF challenge. RESULTS: ABCC4 expression was 3-fold lower in ectocervical tissues compared with endocervical, whereas CYP3A5 was 2-fold higher. IL-6 was correlated with ABCB1 (r = 0.52, P = 0.01) and ABCG2 (r = 0.56, P =0.005). Dose-normalized phosphorylation did not differ between endo- and ectocervix (P > 0.5). Infectivity of explants was low (53%) but did not differ by compartment. Intracellular tenofovir diphosphate concentrations were associated with a decrease in ectocervical viral replication (r =0.39, P < 0.05). There was a strong relationship between the proportion of explants infected and emtricitabine dose (P =0.02) but no relationship between intracellular emtricitabine triphosphate and protection. CONCLUSIONS: We identified differences in DMET expression and ARV metabolism between ecto- and endocervical tissues, as well as correlations between DMET and IL-6. Ectocervical explants demonstrated consistent viral infectivity and dose-dependent inhibition. The model is useful in determining tenofovir diphosphate targets.
引用
- Collins LB, Le A, Nicol MR, et al. Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model. J Antimicrob Chemother. 2026. PMID: 41873439. doi:10.1093/jac/dkag103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。